TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Israely, Tomer ^a   Melamed, Sharon ^a   Achdout, Hagit ^a   Erez, Noam ^a   Politi, Boaz ^a   Waner, Trevor ^a   Lustig, Shlomo ^a   Paran, Nir ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; SMALLPOX VACCINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; VIRUS ANTIGEN; LIVE VACCINE; OLIGODEOXYRIBONUCLEOTIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DEATH; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; MOUSE; MOUSEPOX; NATURAL KILLER CELL; NONHUMAN; POST EXPOSURE PROPHYLAXIS; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; WEIGHT REDUCTION; AGONISTS; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; IMMUNOLOGY; METABOLISM; MORTALITY; SMALLPOX; VACCINATION; VIROLOGY;

VARIOLA VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; IMMUNOMODULATION; INTERFERON-GAMMA; MICE; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; SMALLPOX; SMALLPOX VACCINE; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; VACCINATION; VACCINES, ATTENUATED; VIRAL LOAD;

EID: 84908635010     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/Journal.pone.0110545     Document Type: Article

References (58)

1. Fenner F (1982) A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 4: 916-930.
2. Henderson DA (1999) The looming threat of bioterrorism. Science 283: 1279-1282.
3. Mortimer PP (2003) Can postexposure vaccination against smallpox succeed? Clin Infect Dis 36: 622-629.
4. Cross J (1821) A history of the variolous epidemic which occurred in Norwich, in the year 1819, and destroyed 530 individuals; with an estimate of the protection afforded by vaccination, and a review of past and present opinions upon chicken-pox and modified smallpox.; J EM, editor.
5. Esteban D, Parker S, Schriewer J, Hartzler H, Buller RM (2012) Mousepox, a small animal model of smallpox. Methods Mol Biol 890: 177-198.
6. Esteban DJ, Buller RM (2005) Ectromelia virus: the causative agent of mousepox. J Gen Virol 86: 2645-2659.
7. Israely T, Paran N, Lustig S, Erez N, Politi B, et al. (2012) A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease. Virol J 9: 119.
8. Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, et al. (2009) Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 199: 39-48.
9. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, et al. (2010) A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol 84: 3909-3920.
10. Parker S, Touchette E, Oberle C, Almond M, Robertson A, et al. (2008) Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 77: 39-49.
11. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, et al. (2007) Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 51: 689-695.
12. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, et al. (2009) Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27: 1691-1699.
13. Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19: 1597-1608.
14. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
15. Sasai M, Yamamoto M (2013) Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors. Int Rev Immunol 32: 116-133.
16. Lester SN, Li K (2014) Toll-like receptors in antiviral innate immunity. J Mol Biol 426: 1246-1264.
17. Arpaia N, Barton GM (2011) Toll-like receptors: key players in antiviral immunity. Curr Opin Virol 1: 447-454.
18. Hanagata N (2012) Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine 7: 2181-2195.
19. Vilaysane A, Muruve DA (2009) The innate immune response to DNA. Semin Immunol 21: 208-214.
20. Matsumoto M, Seya T (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60: 805-812.
21. Tatematsu M, Seya T, Matsumoto M (2014) Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses. Biochem J 458: 195-201.
22. Zhang SY, Herman M, Ciancanelli MJ, Perez de Diego R, Sancho-Shimizu V, et al. (2013) TLR3 immunity to infection in mice and humans. Curr Opin Immunol 25: 19-33.
23. Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
24. Lau YF, Tang LH, Ooi EE (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27: 1354-1364.
25. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, et al. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5: e1000373.
26. Skountzou I, Martin Mdel P, Wang B, Ye L, Koutsonanos D, et al. (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28: 4103-4112.
27. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, et al. (2011) Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29: 4897-4902.
28. Coban C, Horii T, Akira S, Ishii KJ (2010) TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine. Expert Rev Vaccines 9: 775-784.
29. Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, et al. (2013) TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. Hum Vaccin Immunother 9.
30. Kundi M (2007) New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6: 133-140.
31. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197.
32. Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, et al. (2007) A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25: 1214-1224.
33. Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, et al. (2007) Adjuvantenhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25: 2787-2799.
34. Golden JW, Josleyn M, Mucker EM, Hung CF, Loudon PT, et al. (2012) Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One 7: e42353.
35. Knopf HL, Blacklow NR, Glassman MI, Cline WL, Wong VG (1971) Antibody in tears following intranasal vaccination with inactivated virus. II. Enhancement of tear antibody production by the use of polyinosinic: polycytidilic acid (poly I:C). Invest Ophthalmol 10: 750-759.
36. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, et al. (2008) Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118: 1776-1784.
37. Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, Ember SW, et al. (2013) Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol 94: 2367-2392.
38. Xu RH, Rubio D, Roscoe F, Krouse TE, Truckenmiller ME, et al. (2012) Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver. PLoS Pathog 8: e1002475.
39. Paran N, Lustig S, Zvi A, Erez N, Israely T, et al. (2013) Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response. Virol J 10: 229.
40. Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, et al. (2012) Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 8: e1002557.
41. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoint. Am J Hyg 493-497.
42. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, et al. (2004) Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A 101: 15196-15200.
43. Jurado A, Carballido J, Griffel H, Hochkeppel HK, Wetzel GD (1989) The immunomodulatory effects of interferon-gamma on mature B-lymphocyte responses. Experientia 45: 521-526.
44. Reynolds DS, Boom WH, Abbas AK (1987) Inhibition of B lymphocyte activation by interferon-gamma. J Immunol 139: 767-773.
45. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, et al. (2010) A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28: 6627-6636.
46. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79: 2910-2919.
47. Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, et al. (2013) Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine 31: 319-326.
48. Xu RH, Cohen M, Tang Y, Lazear E, Whitbeck JC, et al. (2008) The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med 205: 981-992.
49. Liu G, Zhai Q, Schaffner DJ, Wu A, Yohannes A, et al. (2004) Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol Med Microbiol 40: 201-206.
50. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
51. Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev 127: 157-182.
52. Levy HB, Lvovsky E (1978) Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J Infect Dis 137: 78-81.
53. Walsh KB, Teijaro JR, Brock LG, Fremgen DM, Collins PL, et al. (2014) Animal model of respiratory syncytial virus: CD8+ T cells cause cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol
54. Holechek SA, Denzler KL, Heck MC, Schriewer J, Buller RM, et al. (2013) Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses. PLoS One 8: e77879.
55. Earl PL, Americo JL, Moss B (2012) Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response. J Virol 86: 9105-9112.
56. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, et al. (2003) Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100: 9458-9463.
57. Goulding J, Bogue R, Tahiliani V, Croft M, Salek-Ardakani S (2012) CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J Immunol 189: 2432-2440.
58. Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G (2014) Rapid expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. J Virol.